Charuhas Deshpande, MD
Pathology and Laboratory Medicine
Sees patients age 18 and up
Penn Pathology and Laboratory Medicine HUP
Penn Medicine Provider

About me

  • Associate Professor of Clinical Pathology and Laboratory Medicine

My areas of clinical expertise:

Pulmonary and Mediastinal Pathology,

Cardiovascular Pathology,

Genitourinary Pathology

Education and training

  • Medical School: University of Mumbai (formerly Bombay)
  • Residency: K B Bhabha Municipal Hospital
  • Residency: Seth G.S. Medical College
  • Residency: Tata Memorial Hospital
  • Residency: The Children's Hospital at OU Medical Center
  • Residency: Northwestern Memorial Hospital
  • Fellowship: Tata Memorial Hospital
  • Fellowship: Memorial Sloan-Kettering Cancer Center

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Pennsylvania Hospital: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Dr. Deshpande is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

Pavlisko EN, Neely ML, Wikenheiser-Brokamp KA, Fishbein GA, Litzky L, Farver CF, Pal P, He M, Illei PB, Deshpande C, Robien MA, Kirchner J, Frankel CW, Lang JE, Belperio JA, Palmer SM, Sweet SC; Clinical Trials and Organ Transplantation (CTOT)-47 consortium. Diagnostic alignment to optimize inter-rater reliability among lung transplant pathologists , J Heart Lung Transplant, 44(2): 2025,173-181


Marmarelis ME, Scholes DG, McGrath CM, Priore SF, Roth JJ, Feldman M, Morrissette JJD, Litzky L, Deshpande C, Thompson JC, Doucette A, Gabriel PE, Sun L, Singh AP, Cohen RB, Langer CJ, Carpenter EL, Aggarwal C. Brief Report: Impact of Reflex Testing on Tissue-Based Molecular Genotyping in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer , Clin Lung Cancer, 25(3): 2024,262-265.e2


Kennedy GT, Azari FS, Bernstein E, Deshpande C, Kucharczuk JC, Delikatny EJ, Singhal S. Three-Dimensional Near-Infrared Specimen Mapping Can Identify the Distance from the Tumor to the Surgical Margin During Resection of Pulmonary Ground Glass Opacities , Mol Imaging Biol , 25(1): 2023,203-211


Clifford W Sandlin, Song Gu, Jun Xu, Charuhas Deshpande, Michael D Feldman, Matthew C Good Epithelial cell size dysregulation in human lung adenocarcinoma , PLoS One, 17(10): 2022


Kennedy GT, Azari FS, Bernstein E, Marfatia I, Din A, Deshpande C, Galvis N, Sorger J, Kucharczuk JC, Singhal S. First-in-human results of targeted intraoperative molecular imaging for visualization of ground glass opacities during robotic pulmonary resection , Transl Lung Cancer Res, 11(8): 2022,1567-1577


Abdeen S, Bdeir K, Abu-Fanne R, Maraga E, Higazi M, Khurram N, Feldman M, Deshpande C, Litzky LA, Heyman SN, Montone KT, Cines DB, Higazi AA. Alpha-defensins: risk factor for thrombosis in COVID-19 infection. , British Journal of Haematology, 194(1): 2021,44-52


Bryski MG, Frenzel-Sulyok LG, Delikatny EJ, Deshpande C, Litzky LA, Singhal S. Molecular imaging can identify the location to perform a frozen biopsy during intraoperative frozen section consultation. , PLoS One, 16(6): 2021,e0252731


Predina JD, Haas AR, Martinez M, O'Brien S, Moon EK, Woodruff P, Stadanlick J, Corbett C, Frenzel-Sulyok L, Bryski MG, Eruslanov E, Deshpande C, Langer C, Aguilar LK, Guzik BW, Manzanera AG, Aguilar-Cordova E, Singhal S, Albelda SM. Neoadjuvant Gene-Mediated Cytotoxic Immunotherapy for Non-Small-Cell Lung Cancer: Safety and Immunologic Activity , Molecular Therapy, 29(2): 2021,658-670


Thompson JC, Davis C, Deshpande C, Hwang WT, Jeffries S, Huang A, Mitchell TC, Langer CJ, Albelda SM. Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma , J Immunother Cancer., 8(2): 2020,e000974


Bauml JM, Mick R, Ciunci C, Aggarwal C, Davis C, Evans T, Deshpande C, Miller L, Patel P, Alley E, Knepley C, Mutale F, Cohen RB, Langer CJ. Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer: A Phase 2 Trial. , JAMA Oncology, 1(2): 2019,1283-1290